The TRYNGOLZA launch miss is the key negative surprise, cutting the flagship product's 2026 outlook in half. Monitor Q4 2026 TRYNGOLZA sales and any further guidance changes; the DAWNZERA and ZANVASTRO launches and partnered pipeline (HIBSAGO, sefaxersen, ulefnersen) provide offsetting catalysts.
Drugs in focus
IONS drug pipeline →sefaxersen
▲ Bullish Named in this 8-K- Impact
- Phase
- Phase 3
- Time to market
- Regulatory submission is expected soon — Roche plans to share data with health authorities to seek approval. If filed under standard review, potential approval could come in 2027-2028. The timeline depends on Roche's submission strategy and whether the FDA grants expedited review pathways.
- Next catalyst
- None dated
What to watchThe Phase 3 success is a major derisking event, but the stock hasn't rallied, watch for regulatory submission timing from Roche and the week 105 eGFR data, which will determine the full approval path. The stock near its 52-week low with strong analyst support and a deep pipeline (bepirovirsen/HIBSAGO just approved, zilganersen PDUFA passed) creates an asymmetric risk/reward for investors willing to wait for regulatory milestones.
How the stock moved after the report
BEARISH VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 9 $31.00entry
- T+1 · 7d ago −9.06%α −8.70% · $28.19
- T+5 · 16h ago −9.65%α −7.95% · $28.01
- T+20 · in 21d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Total revenue, DAWNZERA guidance, operating loss and cash guidance were reaffirmed.
Key Financial Metrics
Key Facts
- TRYNGOLZA 2026 product sales guidance lowered to ~$50M from $100-110M
- DAWNZERA 2026 product sales guidance reaffirmed at $110-120M
- Total revenue guidance reaffirmed at $875-900M
- Cash and short-term investments $1.9B as of Sep 30, 2026
- ZANVASTRO (zilganersen) launched for Alexander disease with first patients dosed
- SPINRAZA royalties $69M in Q3 2026, up 23% YoY
- Positive Phase 3 data for sefaxersen (IgAN) and ulefnersen (FUS-ALS)
Financial Impact
TRYNGOLZA product sales guidance cut by ~$50-60M from prior $100-110M to ~$50M; total revenue guidance unchanged at $875-900M
Risk Factors
- TRYNGOLZA sHTG launch may continue to underperform expectations
- Operating expenses rising with commercial investments; cash burn $800M+ in 9 months
- Pipeline setbacks possible (pelacarsen Lp(a) HORIZON data not achieved in 2026)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001140361-26-042598 |
| Document: ef20085128_8k.htm | 0001140361-26-042598 |
| Document: 0001140361-26-042598-index-headers.html | 0001140361-26-042598 |
| Document: 0001140361-26-042598-index.html | 0001140361-26-042598 |
| Document: 0001140361-26-042598.txt | 0001140361-26-042598 |
| 8-K Data (Synthetic) | 0001140361-26-042598 |
Track record
26 reports on IONS
6 of 9 bullish or bearish reports moved the stock their way by T+5. Best: +32.25% at T+60 after the Jul 9, 2026 report. 8 of 9 went positive at some point.
Filters
- Nov 9, 20267d ago 8-K Bearish 6/10 Viewing Entry $31.00 to $28.01 Now $28.01 +9.65% ▲ +9.65% +7.95% vs SPY
- Oct 27, 202620d ago Institutional Cluster Mixed 4/10 Entry $44.90 to $40.15 Now $28.01 −37.62% ▼ −10.58% −9.87% vs SPY
- Oct 23, 202624d ago 8-K Bullish 7/10 Entry $42.93 to $43.52 Now $28.01 −34.75% ▲ +1.37% +1.93% vs SPY
- Oct 21, 202626d ago 8-K Bullish 7/10 Entry $43.91 to $44.39 Now $28.01 −36.21% ▲ +1.09% +0.39% vs SPY
- Oct 21, 202626d ago Institutional Cluster Mixed 3/10 Entry $43.91 to $44.39 Now $28.01 −36.21% ▲ +1.09% +0.39% vs SPY
- Sep 23, 20267w ago 8-K Bullish 7/10 Entry $43.93 to $44.65 Now $28.01 −36.24% ▲ +1.64% +2.31% vs SPY
- Sep 4, 202610w ago 8-K Bearish 7/10 Entry $56.71 to $47.25 Now $28.01 +50.61% ▲ +16.68% +15.56% vs SPY
- Sep 4, 202610w ago 8-K Bullish 7/10 Entry $58.09 to $51.44 Now $28.01 −51.78% ▼ −11.45% −10.24% vs SPY
- Jul 31, 202615w ago Insider Buy Neutral 4/10 Entry $54.49 to $56.94 Now $28.01 −48.60% ▲ +4.50% +2.47% vs SPY
- Jul 29, 202615w ago 8-K Neutral 5/10 Entry $54.04 to $54.19 Now $28.01 −48.17% ▲ +0.28% −5.25% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers